Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Stock Information for Renesola Ltd. ADR

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Renesola Ltd. ADR

Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17
Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement
Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice ("GMP") Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin
Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform
Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement
Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin
Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.